Short Interest in Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Declines By 91.8%

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the recipient of a large decline in short interest during the month of August. As of August 14th, there was short interest totaling 39 shares, a decline of 91.8% from the July 30th total of 474 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days. Currently, 0.0% of the company’s shares are short sold.

Basilea Pharmaceutica Stock Performance

BPMUF stock opened at $77.40 on Wednesday. The company has a fifty day moving average price of $63.19 and a 200-day moving average price of $66.89. Basilea Pharmaceutica has a 52-week low of $59.29 and a 52-week high of $77.40. The company has a quick ratio of 4.68, a current ratio of 5.11 and a debt-to-equity ratio of 0.59.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.

Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.